European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group …
…, P Albers, W Albrecht, F Algaba, M Bamberg, I Bodrogi… - European urology, 2008 - Elsevier
OBJECTIVES: The first consensus report presented by the European Germ Cell Cancer
Consensus Group (EGCCCG) in the year 2004 has found widespread approval by many …
Consensus Group (EGCCCG) in the year 2004 has found widespread approval by many …
[HTML][HTML] European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)
…, N Aass, F Algaba, M Bamberg, I Bodrogi… - Annals of …, 2004 - Elsevier
Germ cell tumour is the most frequent malignant tumour type in young men with a 100% rise
in the incidence every 20 years. Despite this, the high sensitivity of germ cell tumours to …
in the incidence every 20 years. Despite this, the high sensitivity of germ cell tumours to …
Cognitive color
…, T Swartling, U Berggrund, P Bodrogi - Color Research & …, 2004 - Wiley Online Library
This report surveys cognitive aspects of color in terms of behavioral, neuropsychological, and
neurophysiological data. Color is usually defined as a color stimulus or as perceived color. …
neurophysiological data. Color is usually defined as a color stimulus or as perceived color. …
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
…, J Sosman, D McDermott, I Bodrogi… - … England Journal of …, 2007 - Mass Medical Soc
Background Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited
efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of …
efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of …
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
…, S Hansen, JP Machiels, I Kocak, G Gravis, I Bodrogi… - The Lancet, 2010 - thelancet.com
Background Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in
docetaxel-resistant cancers. We aimed to compare the efficacy and safety of cabazitaxel plus …
docetaxel-resistant cancers. We aimed to compare the efficacy and safety of cabazitaxel plus …
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
…, B Melichar, E Bajetta, V Gorbunova, JO Bay, I Bodrogi… - The Lancet, 2007 - thelancet.com
Background Vascular endothelial growth factor (VEGF) inhibition is a valid therapeutic
approach in renal cell carcinoma. Therefore, an investigation of the combination treatment of the …
approach in renal cell carcinoma. Therefore, an investigation of the combination treatment of the …
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized …
…, L Dogliotti, T Oliver, MJ Moore, I Bodrogi… - Journal of clinical …, 2000 - ascopubs.org
PURPOSE: Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and
cisplatin (MVAC) were compared in patients with locally advanced or metastatic transitional-…
cisplatin (MVAC) were compared in patients with locally advanced or metastatic transitional-…
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
…, D Vorobiof, R Duarte, M Gil Gil, I Bodrogi… - Journal of Clinical …, 1999 - ascopubs.org
PURPOSE: This phase III study compared docetaxel and doxorubicin in patients with metastatic
breast cancer who had received previous alkylating agent–containing chemotherapy. …
breast cancer who had received previous alkylating agent–containing chemotherapy. …
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior …
Purpose This multinational, double-blind, randomized, placebo-controlled, phase III trial
assessed the efficacy and tolerability of the oral platinum analog satraplatin in patients with …
assessed the efficacy and tolerability of the oral platinum analog satraplatin in patients with …
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non–small-cell lung cancer
…, M Pesek, I Špásová, CP Belani, I Bodrogi… - Journal of clinical …, 2007 - ascopubs.org
Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor
receptor-2 and epidermal growth factor receptor kinase activity. The activity of vandetanib plus …
receptor-2 and epidermal growth factor receptor kinase activity. The activity of vandetanib plus …